Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- About
CSTL 
Castle Biosciences Inc (CSTL)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
02/26/2026: CSTL (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
9 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $48.12
1 Year Target Price $48.12
| 8 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 899.89M USD | Price to earnings Ratio - | 1Y Target Price 48.12 |
Price to earnings Ratio - | 1Y Target Price 48.12 | ||
Volume (30-day avg) 9 | Beta 1.05 | 52 Weeks Range 14.59 - 44.28 | Updated Date 02/26/2026 |
52 Weeks Range 14.59 - 44.28 | Updated Date 02/26/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.44 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date 2026-03-04 | When - | Estimate -0.3486 | Actual - |
Profitability
Profit Margin -3.56% | Operating Margin (TTM) -8.19% |
Management Effectiveness
Return on Assets (TTM) -1.72% | Return on Equity (TTM) -2.7% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 406276086 | Price to Sales(TTM) 2.62 |
Enterprise Value 406276086 | Price to Sales(TTM) 2.62 | ||
Enterprise Value to Revenue 1.17 | Enterprise Value to EBITDA 12.47 | Shares Outstanding 29188659 | Shares Floating 24570137 |
Shares Outstanding 29188659 | Shares Floating 24570137 | ||
Percent Insiders 2.9 | Percent Institutions 95.02 |
Upturn AI SWOT
Castle Biosciences Inc
Company Overview
History and Background
Castle Biosciences Inc. was founded in 2007 with the mission to commercialize proprietary genomic and biological tests that improve the management of cancer. The company went public in 2019. Key milestones include the launch of its flagship DecisionDx-Melanoma test and subsequent expansion into other dermatologic cancers.
Core Business Areas
- Dermatology: Focuses on developing and commercializing proprietary tests for the diagnosis and management of skin cancers, including melanoma and cutaneous squamous cell carcinoma.
- Ophthalmology: Developing diagnostic and prognostic tests for eye conditions, with a focus on ocular melanoma.
Leadership and Structure
Castle Biosciences is led by a management team with extensive experience in the life sciences and diagnostics industry. The company operates with a functional organizational structure, with teams dedicated to research and development, commercialization, regulatory affairs, and operations.
Top Products and Market Share
Key Offerings
- DecisionDx-Melanoma: A proprietary genomic expression profile test that assists dermatologists in stratifying the risk of melanoma recurrence and metastasis. It is widely used in the US and has shown to improve patient management decisions. Competitors include traditional staging methods and other risk assessment tools, but Castle's proprietary technology offers a distinct advantage. Specific market share data is proprietary but it's considered a leader in its segment.
- DecisionDx-SCC: A gene expression profile test for cutaneous squamous cell carcinoma (cSCC) that helps identify patients at higher risk for metastasis. Similar to DecisionDx-Melanoma, it aims to provide more personalized risk stratification. Competitors are emerging in this space, but Castle Biosciences holds an early mover advantage.
- IDGenetix: A proprietary test for ocular melanoma, designed to improve the management of uveal melanoma patients. This is a newer offering in a niche market.
Market Dynamics
Industry Overview
The diagnostics industry, particularly in oncology and dermatology, is characterized by increasing demand for personalized medicine, advanced genomic testing, and improved risk stratification tools. Technological advancements and a growing understanding of disease biology are driving innovation.
Positioning
Castle Biosciences is positioned as a leader in developing and commercializing proprietary genomic and biological tests for dermatologic cancers. Its competitive advantages lie in its scientifically validated tests, strong intellectual property portfolio, established commercial infrastructure, and focus on unmet clinical needs.
Total Addressable Market (TAM)
The TAM for dermatologic cancer diagnostics is substantial and growing, driven by increasing cancer incidence and the demand for more accurate diagnostic and prognostic tools. Castle Biosciences is well-positioned to capture a significant portion of this market with its innovative tests.
Upturn SWOT Analysis
Strengths
- Proprietary genomic and biological tests with strong clinical validation.
- Established market presence and physician adoption for key products.
- Experienced management team with a track record in diagnostics.
- Focus on unmet clinical needs in underserved cancer markets.
- Strong intellectual property portfolio.
Weaknesses
- Reliance on a few key products for revenue.
- Potential for competition from larger, well-established diagnostic companies.
- Reimbursement challenges and variability.
- Long sales cycles for new product adoption.
Opportunities
- Expansion into new geographic markets.
- Development of new tests for other cancer types or diseases.
- Strategic partnerships and collaborations.
- Increased adoption of precision medicine in healthcare.
- Potential for further clinical utility studies to expand test indications.
Threats
- Changes in healthcare reimbursement policies.
- Emergence of disruptive technologies or alternative diagnostic methods.
- Increased competition from existing or new players.
- Regulatory hurdles for new product approvals.
- Economic downturns impacting healthcare spending.
Competitors and Market Share
Key Competitors
- Exact Sciences Corporation (EXAS)
- Myriad Genetics Inc. (MYGN)
- Guardant Health, Inc. (GH)
Competitive Landscape
Castle Biosciences differentiates itself through its proprietary technology and focus on specific dermatologic indications. While competitors like Exact Sciences and Myriad Genetics have broader oncology portfolios, Castle's specialized approach and strong clinical validation in its niche markets provide a competitive edge. However, larger companies have greater resources for sales and marketing.
Growth Trajectory and Initiatives
Historical Growth: Castle Biosciences has shown a strong historical growth trajectory, driven by the increasing adoption of its DecisionDx-Melanoma test and the successful launch of new products. Revenue has grown substantially in recent years.
Future Projections: Analysts project continued revenue growth for Castle Biosciences, supported by market expansion and the development of new diagnostic solutions. The company is expected to benefit from the growing demand for personalized medicine in oncology.
Recent Initiatives: Recent initiatives include expanding the sales force, investing in R&D for new product development, and pursuing broader clinical utility studies to support reimbursement and physician adoption.
Summary
Castle Biosciences Inc. is a strong player in the dermatologic diagnostics market, demonstrating consistent revenue growth and robust profit margins with its proprietary genomic tests. Its key strength lies in its scientifically validated products and established market presence. However, the company needs to monitor evolving reimbursement policies and potential competition from larger, well-resourced diagnostic firms. Continued investment in R&D and market expansion will be crucial for sustaining its growth trajectory.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company Investor Relations Filings (e.g., 10-K, 10-Q)
- Financial Data Aggregators (e.g., Yahoo Finance, Bloomberg)
- Industry Research Reports
Disclaimers:
This analysis is based on publicly available information and is for informational purposes only. It does not constitute investment advice. Financial data and market share estimates are subject to change and may be subject to proprietary methodologies.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Castle Biosciences Inc
Exchange NASDAQ | Headquaters Friendswood, TX, United States | ||
IPO Launch date 2019-07-25 | Founder, CEO, President & Director Mr. Derek J. Maetzold | ||
Sector Healthcare | Industry Diagnostics & Research | Full time employees 823 | Website https://castlebiosciences.com |
Full time employees 823 | Website https://castlebiosciences.com | ||
Castle Biosciences, Inc., a molecular diagnostics company, provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), uveal melanoma, and mental health conditions. The company offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test that predicts the risk of metastasis for patients with uveal melanoma; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a risk stratification spatial-omics test to predict future development of progression of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, and low-grade dysplasia BE. It also provides DecisionDx-UM, a risk stratification GEP test that predicts the risk of metastasis for patients with uveal melanoma; and IDgenetix, a pharmacogenomic test that helps guide optimal drug treatment for patients diagnosed with major depressive disorder, schizophrenia, bipolar disorder, anxiety disorders, social phobia, obsessive-compulsive personality disorder, post-traumatic stress disorder, and attention deficit hyperactivity disorder. The company offers its products to skin cancer and gastroenterology markets. The company was incorporated in 2007 and is headquartered in Friendswood, Texas.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.